Similarly, rosiglitazone upregulated LRP1 expression at both the mRNA and protein levels, via PPARγ activation [83]. In vivo studies utilizing AD models need to be performed to validate the role of PPARγ agonists and LRP1 in AD. This evidence concerns the gene LRP1 and Alzheimer disease.